Adalvo will submit the DCP for Fidaxomicin 200mg tablets in June 2025, highlighting our commitment to expanding access to high-value antibiotic treatments across global markets, including the U.S.
Based on the reference brand Dificlir, Fidaxomicin is indicated for the treatment of Clostridioides Difficile Infections (CDI), a serious and potentially life-threatening condition.
With global sales reaching approximately $520 million in 2024 and a 3-year CAGR of 14% (IQVIA), Fidaxomicin continues to demonstrate strong commercial demand.
Following successful pivotal BE studies, Adalvo demonstrates its proven ability to execute complex, high-value antibiotic developments.
There are no half-measures at Adalvo – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Contact Our Team To Explore Commercial Opportunities
Partner up now!